Targeting Ergosterol Biosynthesis in Leishmania donovani: Essentiality of Sterol 14alpha-demethylase

HW Murray, 2005, Advances in leishmaniasis, Lancet, 366, 1561, 10.1016/S0140-6736(05)67629-5

LI McCall, 2014, Determinants of disease phenotype in trypanosomatid parasites, Trends in Parasitology, 30, 342, 10.1016/j.pt.2014.05.001

LI McCall, 2013, Determinants for the development of visceral leishmaniasis disease, PLoS Pathog, 9, e1003053, 10.1371/journal.ppat.1003053

P Desjeux, 2004, Leishmaniasis: current situation and new perspectives, Comp Immunol Microbiol Infect Dis, 27, 305, 10.1016/j.cimid.2004.03.004

J Alvar, 2012, Leishmaniasis Worldwide and Global Estimates of Its Incidence, Plos One, 7, e35671, 10.1371/journal.pone.0035671

PJ Hotez, 2014, The global burden of disease study 2010: interpretation and implications for the neglected tropical diseases, PLoS Negl Trop Dis, 8, e2865, 10.1371/journal.pntd.0002865

S Sundar, 2010, Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India, New England Journal of Medicine, 362, 504, 10.1056/NEJMoa0903627

EA Khalil, 2014, Safety and Efficacy of Single Dose versus Multiple Doses of AmBisome(R) for Treatment of Visceral Leishmaniasis in Eastern Africa: A Randomised Trial, PLoS Negl Trop Dis, 8, e2613, 10.1371/journal.pntd.0002613

B Monge-Maillo, 2013, Therapeutic options for visceral leishmaniasis, Drugs, 73, 1863, 10.1007/s40265-013-0133-0

GI Lepesheva, 2011, Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis, Current topics in medicinal chemistry, 11, 2060, 10.2174/156802611796575902

W de Souza, 2009, Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs, Interdisciplinary perspectives on infectious diseases, 2009, 642502, 10.1155/2009/642502

TY Hargrove, 2011, Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum, J Biol Chem, 286, 26838, 10.1074/jbc.M111.237099

JY Choi, 2014, Drug Strategies Targeting CYP51 in Neglected Tropical Diseases, Chemical Reviews

W Xu, 2014, Sterol Biosynthesis Is Required for Heat Resistance but Not Extracellular Survival in Leishmania, PLoS Pathog, 10, e1004427, 10.1371/journal.ppat.1004427

R Reithinger, 2007, Cutaneous leishmaniasis, The Lancet infectious diseases, 7, 581, 10.1016/S1473-3099(07)70209-8

JD Berman, 1982, In vitro susceptibility of antimony-resistant Leishmania to alternative drugs, The Journal of infectious diseases, 145, 279, 10.1093/infdis/145.2.279

A Gebre-Hiwot, 1993, The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis, The Journal of antimicrobial chemotherapy, 32, 837, 10.1093/jac/32.6.837

DH Beach, 1988, Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes, Molecular and Biochemical Parasitology, 31, 149, 10.1016/0166-6851(88)90166-1

HM Al-Abdely, 1999, Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases, Antimicrobial Agents and Chemotherapy, 43, 2910, 10.1128/AAC.43.12.2910

JP Gangneux, 1999, Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum, Antimicrobial Agents and Chemotherapy, 43, 172, 10.1128/AAC.43.1.172

DT Hart, 1989, Perturbation of sterol biosynthesis by itraconazole and ketoconazole in Leishmania mexicana mexicana infected macrophages, Molecular and Biochemical Parasitology, 33, 123, 10.1016/0166-6851(89)90026-1

JD Berman, 1986, Effects of Ketoconazole on Sterol Biosynthesis by Leishmania-Mexicana Mexicana Amastigotes in Murine Macrophage Tumor-Cells, Molecular and Biochemical Parasitology, 20, 85, 10.1016/0166-6851(86)90145-3

JD Berman, 1987, In vitro antileishmanial activity of inhibitors of steroid biosynthesis and combinations of antileishmanial agents, The Journal of parasitology, 73, 671, 10.2307/3282158

LJ Goad, 1985, Sterols of ketoconazole-inhibited Leishmania mexicana mexicana promastigotes, Molecular and Biochemical Parasitology, 15, 257, 10.1016/0166-6851(85)90089-1

LI McCall, 2012, Involvement of the Leishmania donovani virulence factor A2 in protection against heat and oxidative stress, Exp Parasitol, 132, 109, 10.1016/j.exppara.2012.06.001

M Aslett, 2010, TriTrypDB: a functional genomic resource for the Trypanosomatidae, Nucleic Acids Research, 38, D457, 10.1093/nar/gkp851

SM Murta, 2009, Methylene tetrahydrofolate dehydrogenase/cyclohydrolase and the synthesis of 10-CHO-THF are essential in Leishmania major, Mol Microbiol, 71, 1386, 10.1111/j.1365-2958.2009.06610.x

KA Robinson, 2003, Improvements in transfection efficiency and tests of RNA interference (RNAi) approaches in the protozoan parasite Leishmania, Molecular and Biochemical Parasitology, 128, 217, 10.1016/S0166-6851(03)00079-3

E Medinaacosta, 1993, Rapid Isolation of DNA from Trypanosomatid Protozoa Using a Simple Mini-Prep Procedure, Molecular and Biochemical Parasitology, 59, 327, 10.1016/0166-6851(93)90231-L

KJ Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method, Methods, 25, 402, 10.1006/meth.2001.1262

T Downing, 2011, Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance, Genome Research, 21, 2143, 10.1101/gr.123430.111

LI McCall, 2010, Localization and induction of the A2 virulence factor in Leishmania: evidence that A2 is a stress response protein, Mol Microbiol, 77, 518, 10.1111/j.1365-2958.2010.07229.x

SS Gunatilleke, 2012, Diverse inhibitor chemotypes targeting Trypanosoma cruzi CYP51, PLoS Negl Trop Dis, 6, e1736, 10.1371/journal.pntd.0001736

JY Choi, 2014, R-Configuration of 4-Aminopyridyl-Based Inhibitors of CYP51 Confers Superior Efficacy Against Trypanosoma cruzi, Acs Medicinal Chemistry Letters, 5, 434, 10.1021/ml500010m

JY Choi, 2013, Rational development of 4-aminopyridyl-based inhibitors targeting Trypanosoma cruzi CYP51 as anti-chagas agents, Journal of Medicinal Chemistry, 56, 7651, 10.1021/jm401067s

CM Calvet, 2014, 4-Aminopyridyl-based CYP51 inhibitors as anti-Trypanosoma cruzi drug leads with improved pharmacokinetic profile and in vivo potency, Journal of Medicinal Chemistry, 57, 6989, 10.1021/jm500448u

MB Rogers, 2011, Chromosome and gene copy number variation allow major structural change between species and strains of Leishmania, Genome Research, 21, 2129, 10.1101/gr.122945.111

JM Ubeda, 2014, Genome-wide stochastic adaptive DNA amplification at direct and inverted DNA repeats in the parasite leishmania, PLoS biology, 12, e1001868, 10.1371/journal.pbio.1001868

M Dacher, 2014, Probing druggability and biological function of essential proteins in Leishmania combining facilitated null mutant and plasmid shuffle analyses, Mol Microbiol

B Norris-Mullins, 2014, LmaPA2G4, a Homolog of Human Ebp1, Is an Essential Gene and Inhibits Cell Proliferation in L. major, PLoS Negl Trop Dis, 8, e2646, 10.1371/journal.pntd.0002646

LM Podust, 2007, Small-molecule scaffolds for CYP51 inhibitors identified by high-throughput screening and defined by X-ray crystallography, Antimicrobial Agents and Chemotherapy, 51, 3915, 10.1128/AAC.00311-07

DF Vieira, 2014, Expanding the binding envelope of CYP51 inhibitors targeting Trypanosoma cruzi with 4-Aminopyridyl-based sulfonamide derivatives, Chembiochem: a European journal of chemical biology, 15, 1111, 10.1002/cbic.201402027

CK Chen, 2009, Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit, PLoS Negl Trop Dis, 3, e372, 10.1371/journal.pntd.0000372

PS Doyle, 2010, A nonazole CYP51 inhibitor cures Chagas′ disease in a mouse model of acute infection, Antimicrobial Agents and Chemotherapy, 54, 2480, 10.1128/AAC.00281-10

GI Lepesheva, 2011, Structural basis for conservation in the CYP51 family, Biochimica Et Biophysica Acta, 1814, 88, 10.1016/j.bbapap.2010.06.006

TS Cherkesova, 2014, Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition, Febs Letters, 588, 3878, 10.1016/j.febslet.2014.08.030

MM Kulkarni, 2013, Voriconazole suppresses the growth of Leishmania species in vitro, Parasitology Research, 112, 2095, 10.1007/s00436-013-3274-x

AE Paniz Mondolfi, 2011, Successful treatment of Old World cutaneous leishmaniasis caused by Leishmania infantum with posaconazole, Antimicrobial Agents and Chemotherapy, 55, 1774, 10.1128/AAC.01498-10

H Rangel, 1996, Naturally azole-resistant Leishmania braziliensis promastigotes are rendered susceptible in the presence of terbinafine: comparative study with azole-susceptible Leishmania mexicana promastigotes, Antimicrobial Agents and Chemotherapy, 40, 2785, 10.1128/AAC.40.12.2785

PC Cotrim, 1999, Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection, J Biol Chem, 274, 37723, 10.1074/jbc.274.53.37723

SO Lorente, 2005, Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa, Bioorganic & Medicinal Chemistry, 13, 3519, 10.1016/j.bmc.2005.02.060

SO Lorente, 2004, Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis, Antimicrobial Agents and Chemotherapy, 48, 2937, 10.1128/AAC.48.8.2937-2950.2004

N Dinesh, 2014, Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies, Microbial Pathogenesis, 66, 14, 10.1016/j.micpath.2013.11.001

JA Friesen, 2004, The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases, Genome biology, 5, 248, 10.1186/gb-2004-5-11-248

S Verma, 2011, CYP5122A1, a novel cytochrome P450 is essential for survival of Leishmania donovani, Plos One, 6, e25273, 10.1371/journal.pone.0025273

S Kamhawi, 2000, The vectorial competence of Phlebotomus sergenti is specific for Leishmania tropica and is controlled by species-specific, lipophosphoglycan-mediated midgut attachment, Parasitology, 121, 25, 10.1017/S0031182099006125

AK Tzinia, 1991, Substrate-dependent pH optima of gp63 purified from seven strains of Leishmania, Molecular and Biochemical Parasitology, 47, 83, 10.1016/0166-6851(91)90150-5

I Molina, 2014, Randomized trial of posaconazole and benznidazole for chronic Chagas′ disease, The New England journal of medicine, 370, 1899, 10.1056/NEJMoa1313122